Professor Hongfei Duan：Advances in Diagnosis and Treatment of Mycobacterium avium Complex (MAC) Pulmonary Disease

Professor Hongfei Duan：Advances in Diagnosis and Treatment of Mycobacterium avium Complex (MAC) Pulmonary Disease

2024.07.04
Non-tuberculous mycobacteria (NTM) refers to all mycobacteria other than Mycobacterium tuberculosis and Mycobacterium leprae. NTM most commonly affect the lungs, causing NTM pulmonary disease (NTM-PD), which can even lead to disseminated disease in immunocompromised individuals. In recent years, with changes in the environment, updates in detection technology, and increased awareness among physicians, the incidence of NTM-PD has been steadily increasing, with Mycobacterium avium complex (MAC) pulmonary disease being the most common worldwide. At the recent Fourth National Conference of the Chinese Medical Association on Bacterial and Fungal Infections (BISC 2024), Professor Hongfei Duan from the Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, delivered a fascinating presentation titled "Advances in Diagnosis and Treatment of Mycobacterium avium Complex Pulmonary Disease," elucidating and analyzing the current status, challenges, and progress in the diagnosis and treatment of MAC pulmonary disease.
Professor Jingtao Li: Advances in Clinical Research on Traditional Chinese Medicine in the Prevention and Treatment of Liver Fibrosis

Professor Jingtao Li: Advances in Clinical Research on Traditional Chinese Medicine in the Prevention and Treatment of Liver Fibrosis

2024.07.03
Liver fibrosis is the result of damage to the liver by pathogenic factors, leading to chronic, repeated abnormalities in liver function and the deposition of collagen and other proteins. It is a crucial factor influencing the prognosis of chronic liver disease and a necessary stage in the progression to cirrhosis. Recently, at the 25th National Conference on Traditional Chinese Medicine and Hepatobiliary Diseases organized by the Chinese Association of Traditional Chinese Medicine, Professor Jingtao Li from the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine presented the latest clinical research advancements in the prevention and treatment of liver fibrosis using Traditional Chinese Medicine (TCM). The multi-component, multi-target therapeutic features of TCM, along with the significant efficacy of several representative drugs, provide strong scientific support for the application of TCM in combating liver fibrosis.
EHA Expert Interview | Professor Jimin Shi: Better Pre-Transplant Treatment Options for TP53-Mutated MDS Patients: Cytoreductive or Non-Cytoreductive

EHA Expert Interview | Professor Jimin Shi: Better Pre-Transplant Treatment Options for TP53-Mutated MDS Patients: Cytoreductive or Non-Cytoreductive

2024.07.03
Patients with TP53-mutated myelodysplastic syndromes (MDS) generally have poor prognoses and face significant treatment challenges. To improve the survival outcomes of these patients, Professor Jimin Shi's team at The First Affiliated Hospital, Zhejiang University School of Medicine conducted an in-depth investigation into the treatment options for TP53-mutated MDS patients before transplantation. At the recent 29th European Hematology Association (EHA) Annual Meeting, they presented the results of their study (P1367), which compared cytoreductive and non-cytoreductive therapies. To provide a comprehensive understanding of the findings and their implications, "Oncology Frontier - Hematology Frontier" invited Professor Jimin Shi to share insights from this research
EHA in 5 Minutes | Professor Linhua Yang: Latest Advances in Immune Thrombocytopenia Research (Part 1)

EHA in 5 Minutes | Professor Linhua Yang: Latest Advances in Immune Thrombocytopenia Research (Part 1)

2024.07.03
Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder characterized by a low platelet count. At the recently held 29th European Hematology Association (EHA) Annual Meeting, significant advancements were made in the field of ITP. "Oncology Frontier - Hematology Frontier" invited Professor Linhua Yang from the Second Hospital of Shanxi Medical University to select and detail some of the most impactful studies. This issue presents two studies: one on clonal hematopoiesis in ITP and its clinical significance, and the other on the safety and efficacy of avatrombopag for treating chronic ITP in children, with the aim of deepening understanding of ITP and providing new insights for future treatment strategies.
ASCO Five Minutes | Professor Lili Mao Interprets Highlights of Soft Tissue Sarcoma Research at the ASCO Conference

ASCO Five Minutes | Professor Lili Mao Interprets Highlights of Soft Tissue Sarcoma Research at the ASCO Conference

2024.07.03
Soft tissue sarcoma (STS) is a rare and highly heterogeneous malignant tumor, and exploring treatment strategies for it has been a key focus in oncology research. In recent years, with the deepening of molecular biology and immunology research, clinical understanding and treatment methods for these diseases have continually advanced. At the recently concluded 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, several key studies on soft tissue sarcoma released the latest clinical data. "Oncology Frontier" invited Professor Lili Mao from Peking Cancer Hospital to provide an in-depth analysis of these studies, summarizing the current progress in STS treatment research and discussing the clinical significance and future application prospects of these findings.
EHA Expert Interview | Professor Bing Han: New Breakthrough in PNH Treatment – Dual-target Complement Inhibitor Shows Durable Efficacy

EHA Expert Interview | Professor Bing Han: New Breakthrough in PNH Treatment – Dual-target Complement Inhibitor Shows Durable Efficacy

2024.07.03
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and complex blood disorder with limited conventional treatment options, resulting in low survival rates and poor quality of life for patients. Innovative drugs and treatments are urgently needed to improve hemolysis control, reduce the risk of complications, and enhance survival rates and quality of life for these patients. At the 2024 European Hematology Association (EHA) Annual Meeting held in Madrid, Spain, Professor Bing Han from Peking Union Medical College Hospital presented exciting research results. The dual-functional C5 antibody/H factor fusion protein KP104 showed long-term efficacy in previously untreated PNH patients (S187). "Oncology Frontier - Hematology Frontier" conducted an interview with Professor Han to discuss this research and her insights on further optimizing PNH management.
EHA China Spotlight | Professor Jing Pan: Previous-Transplant or New-Match Donor CD5 CAR-T Cells in Pediatric and Adult Relapsed/Refractory T-ALL

EHA China Spotlight | Professor Jing Pan: Previous-Transplant or New-Match Donor CD5 CAR-T Cells in Pediatric and Adult Relapsed/Refractory T-ALL

2024.07.03
CAR-T cell therapy is rapidly advancing in the field of hematologic malignancies, including significant progress in the treatment of T-cell lymphomas. However, challenges such as relapse, off-target effects, and viral infections still need to be addressed to further optimize the effectiveness of CAR-T cell therapy. At the recent 2024 European Hematology Association (EHA) Annual Meeting, the research team led by Professor Jing Pan from Beijing GoBroad Boren Hospital presented notable findings on these issues, which were selected for oral presentations. "Oncology Frontier - Hematology Frontier" conducted an on-site interview with Professor Jing Pan to discuss and interpret these studies, providing valuable guidance and practical recommendations for CAR-T therapy in clinical T-cell lymphoma treatment.
Professor Xiaofan Zhu’s In-depth Analysis of EHA Selected Research on Pediatric MDS

Professor Xiaofan Zhu’s In-depth Analysis of EHA Selected Research on Pediatric MDS

2024.07.03
Pediatric Myelodysplastic Syndromes (MDS) are rare hematologic disorders, with advanced MDS being particularly concerning. At the 29th Annual Meeting of the European Hematology Association (EHA 2024), Professor Xiaofan Zhu's team from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences presented multiple studies, including two key studies on pediatric MDS. These studies delve into crucial issues and provide significant academic references to optimize the diagnosis and treatment of pediatric MDS. In this issue of "Oncology Frontier - Hematology Frontier," we report the results of these studies and feature an exclusive detailed interpretation by Professor Xiaofan Zhu.